Delivery Order 75N95022D00019-75N95024F00002
Award Date
3/21/24
Potential Completion Date
4/23/25
Potential Value
$211K
Federal Agency
National Institute on Drug Abuse
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost Plus Fixed Fee
Place of Performance
Albuquerque, NM 87108, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Service Contract Act
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the evaluation of a potential respiratory stimulant on behalf of the National Institute on Drug Abuse (NIDA), a component of the National Institutes of Health (NIH). The award, with a ceiling value of $140,848.00, was issued to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The scope of work includes nonclinical animal studies to assess potential treatments for drug-induced respiratory depression and...
The National Institutes of Health's National Institute on Drug Abuse awarded a $148,800 cost-plus-fixed-fee delivery order contract to Lovelace Biomedical Research Institute. The task order is being issued against an existing indefinite-delivery/indefinite-quantity contract vehicle to support the assessment of potential treatments for drug-induced respiratory depression and overdose toxicity from September 26, 2022 through September 30, 2024. Lovelace Biomedical will evaluate methods to...
The Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse awarded a $163,000 cost-plus-fixed-fee delivery order contract to Lovelace Biomedical Research Institute. The contract is for the assessment of potential treatments for drug-induced respiratory depression and overdose toxicity under Task Order 75N95022F00002 of an unspecified multiple award contract vehicle. Lovelace will conduct the assessment from September 2022 through September 2024...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA), a civilian agency, to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The contract is for natural history studies in neuromuscular junction (NMJ) disease mouse models, with a period of performance from September 28, 2020 to December 31, 2021 and a total ceiling value of $2,366,151.00. The contract does not have a set-aside...
This is a $3,108,022.00 cost-plus-fixed-fee delivery order contract awarded by the National Institute on Drug Abuse (NIDA) to the Lovelace Biomedical Research Institute, a non-profit preclinical contract research organization. The contract is for the characterization of a downstream gene therapeutic for the reparative treatment of severe fractures, with a period of performance from September 24, 2020 to November 23, 2021. This contract does not have a set-aside designation. Lovelace Biomedical...
This is a cost-plus-fixed-fee delivery order contract awarded by the National Center for Advancing Translational Sciences (NCATS), a component of the National Institutes of Health (NIH), to the Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $520,896.73 contract is for the evaluation of drug efficacy in a rat model of neuropathic pain. Lovelace Biomedical Research Institute has experience conducting animal studies, including for federal...
This federal contract award, valued at $1,403,705.20, was issued by the Food and Drug Administration (FDA) to Lovelace Biomedical and Environmental Research Institute, Inc. (LBERI), a subsidiary of Lovelace Biomedical Research Institute. The contract is a delivery order issued under the Tobacco Products Pharmacology Study master indefinite-delivery, indefinite-quantity (IDIQ) contract vehicle. The contract does not have a set-aside designation. LBERI, a non-profit contract research organization,...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $486,301.00 cost-plus-fixed-fee delivery order contract to the Lovelace Biomedical Research Institute, a not-for-profit contract research organization. Under this contract, the Lovelace Biomedical Research Institute will perform the transfer, validation, and qualification of bioanalytical methods for the detection of cabotegravir and levonorgestrel in rat and nonhuman primate plasma. This work is being conducted...
This contract was awarded by the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Center for Advancing Translational Sciences to Lovelace Biomedical Research Institute, a not-for-profit preclinical contract research organization. The $179,684.31 contract is for the evaluation of drug efficacy in a guinea pig model of neonatal opioid withdrawal syndrome. This work does not have a set-aside designation. Lovelace Biomedical Research Institute has served...
The Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $716,374 delivery order contract to Lovelace Biomedical Research Institute. Under the terms of the firm fixed price contract, Lovelace Biomedical Research Institute will conduct a Good Laboratory Practice repeat dose toxicology study for BPL-24910 in support of the Comprehensive and Rapid Response for NIAID Research Programs major program code. Performance...